Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934677 | 0.84 | HTT (0.52) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL18471568 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL13268072 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL29229819 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL16330014 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL12855219 | 0.81 | HTT (0.54) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL23961819 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL2223882 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL12713662 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2HPGDHTTALDH1A1MEN1 | |
| SCHEMBL19401301 | 0.80 | HPGD (0.56) | SMN1; SMN2HPGDHTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| CN-107108709-B | FGF21 derivatives and uses thereof | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | disclosed |
| EP-3236991-B1 | FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-06-19 | — | — | EP | disclosed |
| US-10124039-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-11-13 | — | — | US | disclosed |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| US-9895417-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-02-20 | — | — | US | disclosed |
| US-9895417-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-02-20 | — | — | US | disclosed |
| WO-2017220706-A1 | PHARMACEUTICAL COMPOSITIONS OF FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2017-12-28 | — | — | WO | disclosed |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK AS (DK) | 2017-12-14 | — | — | US | disclosed |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK AS (DK) | 2017-12-14 | — | — | US | disclosed |
| EP-3236991-A1 | FGF21 DERIVATIVES AND USES THEREOF | Novo Nordisk A/S (DK) | 2017-11-01 | — | — | EP | disclosed |
| US-9744213-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2017-08-29 | — | — | US | disclosed |
| US-9744213-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2017-08-29 | — | — | US | disclosed |
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| WO-2016102562-A1 | FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2016-06-30 | — | — | WO | disclosed |
| US-20130112572-A1 | NOVEL CHEMISTRY USED IN BIOSENSORS | OHMX CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | SMN1; SMN2 3513/4885HPGD 1303/4885HTT 3093/4885 |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | SMN1; SMN2 3513/4885HPGD 1303/4885HTT 3093/4885 |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | SMN1; SMN2 3691/4885HPGD 531/4885HTT 4061/4885 |
| US-10124039-B2 | FGF21 derivatives and uses thereof | FGF2, FGFR1, FGF1 | SMN1; SMN2 3513/4885HPGD 1303/4885HTT 3093/4885 |
| US-20130112572-A1 | NOVEL CHEMISTRY USED IN BIOSENSORS | GPX1, GPX4, FECH | SMN1; SMN2 4729/4885HPGD 1561/4885HTT 4605/4885 |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | SMN1; SMN2 3513/4885HPGD 1303/4885HTT 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.